Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.
Tiago M de CarvalhoEveline A M HeijnsdijkHarry J de KoningPublished in: Cancer (2017)
Prostate-specific antigen-based prostate cancer screening in the United States between the ages of 55 and 69 years, as recommended by the USPSTF, may be cost-effective at a $100,000 threshold but only with a quadrennial screening frequency and with AS offered to all low-risk men. Cancer 2018;124:507-13. © 2017 American Cancer Society.